Source study found
Story checked
Long-acting injectable antipsychotics provide better outcomes in bipolar disorder and older schizophrenia patients (opens in a new tab)
medicalxpress.com · 2026-09-24
Short answer
Needs reviewStudy found.
We found the study, but the claim check did not finish.
Checked against the study summary. The full text wasn't available, so some details couldn't be settled either way.
Share this check
The story
Long-acting injectable antipsychotics provide better outcomes in bipolar disorder and older schizophrenia patients
medicalxpress.com · 2026-09-24
The story’s checkable claims.
Read the original story (opens in a new tab)NewsLink checks it
We found the study behind this story.
We found the study, but couldn't compare the story to it: the study's evidence could not be profiled.
Open claim evidenceThe source study
Comparison of Long-Acting Injectable and Oral Antipsychotics in Bipolar Disorder
Source layer
The 2 papers the story cites
Source study separated from background citations.
The research anchor for the report.
- The study this story reportsmentioned without context
Disease relapse, all-cause mortality, and adverse events associated with long-acting injectable antipsychotics versus oral antipsychotics in older people with schizophrenia in Hong Kong: a population-based within-subject analysis
The Lancet Psychiatry · 2025
- The study this story reportsmentioned without context
Comparison of Long-Acting Injectable and Oral Antipsychotics in Bipolar Disorder
American Journal of Psychiatry · 2026
Evidence layer
Claim by claim
The source study was found, but the study's evidence could not be profiled, so these claims couldn't be checked.
Reading mode
Scan verdicts. Open evidence only when needed.
Claim 1 of 6Not checkedResearchers at the University of Hong Kong found that long-acting injectable antipsychotics provide better treatment outcomes than oral antipsychotic medications for patients 65 and older with schizophrenia.View evidenceHide evidence
Not checked
The source study was found, but this claim couldn't be checked against it.
Claim 2 of 6Not checkedAmong people with bipolar disorder, LAI antipsychotics were associated with 33% fewer psychiatric hospitalizations than oral antipsychotics.View evidenceHide evidence
As stated33% fewer psychiatric hospitalizations
Not checked
The source study was found, but this claim couldn't be checked against it.
Claim 3 of 6Not checkedAmong older people with schizophrenia, LAI antipsychotics were associated with 29% fewer relapse-related hospital admissions and 77% lower all-cause mortality than oral antipsychotics.View evidenceHide evidence
As stated29% fewer relapse-related hospital admissions; 77% lower all-cause mortality
Not checked
The source study was found, but this claim couldn't be checked against it.
Claim 4 of 6Not checkedThe article says benefits were greatest when LAI antipsychotics were used earlier in the illness, including within two years of first diagnosis.View evidenceHide evidence
Not checked
The source study was found, but this claim couldn't be checked against it.
Claim 5 of 6Not checkedThe story says the studies highlighted the potential value of second-generation LAI formulations and called for careful monitoring because extrapyramidal symptoms may be more likely with first-generation LAI antipsychotics.View evidenceHide evidence
Not checked
The source study was found, but this claim couldn't be checked against it.
Claim 6 of 6Not checkedThe article cites a related self-controlled series study in JAMA Network Open in 2022 reporting 47% fewer hospitalizations for schizophrenia, 44% fewer suicide attempts, and 37% fewer all-cause hospitalizations with LAI antipsychotics.View evidenceHide evidence
As stated47% fewer hospitalizations; 44% fewer suicide attempts; 37% fewer all-cause hospitalizations
Not checked
The source study was found, but this claim couldn't be checked against it.
Method layer
NewsLink found the paper. Tessa takes you deeper.
NewsLink checks the story. Tessa is where you inspect the paper, authors, evidence, and research context.
Open the paper in Tessa
Comparison of Long-Acting Injectable and Oral Antipsychotics in Bipolar Disorder
American Journal of Psychiatry · 2026
Why this one
Confident
NewsLink found the paper. Tessa is where you inspect it deeply.
Papers considered
The selected paper, plus nearby candidates.
Crossref, PubMed, Europe PMC · 17 candidate papers
Comparison of Long-Acting Injectable and Oral Antipsychotics in Bipolar Disorder
American Journal of Psychiatry · 2026 · Crossref
Disease relapse, all-cause mortality, and adverse events associated with long-acting injectable antipsychotics versus oral antipsychotics in older people with schizophrenia in Hong Kong: a population-based within-subject analysis
The Lancet Psychiatry · 2025 · Crossref
Use of Long-acting Injectable Antipsychotic Drugs in the Elderly: A Retrospective Study.
Clinical Psychopharmacology and Neuroscience : the Official Scientific Journal of the Korean College of Neuropsychopharmacology · 2026 · PubMed, Europe PMC
Long-Acting Injectable Versus Oral Antipsychotics in Reducing Hospitalization Outcomes in Schizophrenia: A Repeat Mirror Image Study
2022 · Crossref
Low willingness and patient-caregiver concordance regarding long-acting injectable antipsychotics in schizophrenia cases: a convergent mixed-methods study.
2026 · Europe PMC
Use and Discontinuation Rates of Long-Acting Injectable Antipsychotics Between Race/Ethnicity in Older Adults Using Medicaid Databases.
Journal of the American Geriatrics Society · 2025 · PubMed, Europe PMC
And 11 more candidates considered.